Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema

Oxurion NV announced that it has randomized the last patient in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema .